The Choice Between Immunotherapy and TKIs for Liver Cancer – Targeted Oncology
|
The Choice Between Immunotherapy and TKIs for Liver Cancer
Targeted Oncology Options for treating patients with hepatocellular carcinoma (HCC) may currently be limited, with most physicians turning to a tyrosine kinase inhibitor (TKI) for advanced disease, but physicians may soon be able to choose between a TKI and immunotherapy. |
